Halozyme Therapeutics, Inc.
HALO
$48.70
-$1.53-3.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -11.12% | 2.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.12% | 2.73% | |||
| Cost of Revenue | -17.38% | -7.94% | |||
| Gross Profit | -9.46% | 5.99% | |||
| SG&A Expenses | 0.27% | 2.44% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.67% | -3.45% | |||
| Operating Income | -19.35% | 7.54% | |||
| Income Before Tax | -19.29% | 7.91% | |||
| Income Tax Expenses | -37.54% | 46.44% | |||
| Earnings from Continuing Operations | -13.81% | 0.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.81% | 0.00% | |||
| EBIT | -19.35% | 7.54% | |||
| EBITDA | -17.50% | 6.78% | |||
| EPS Basic | -11.58% | 0.35% | |||
| Normalized Basic EPS | -17.07% | 6.83% | |||
| EPS Diluted | -12.41% | 1.12% | |||
| Normalized Diluted EPS | -17.68% | 7.41% | |||
| Average Basic Shares Outstanding | -2.52% | -0.35% | |||
| Average Diluted Shares Outstanding | -1.81% | -0.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||